Clinical Outcomes Of Using Nebulized Budesonide As The Initial Treatment For Acute Exacerbations Of Chronic Obstructive Pulmonary Disease: A Post-Hoc Analysis
Authors Zheng JP, Zhang J, Ma LJ, Chen P, Huang M, Ou XM, Zhao ZW, Jiang SJ, Cao J, Yao W
Received 30 November 2018
Accepted for publication 12 September 2019
Published 29 November 2019 Volume 2019:14 Pages 2725—2731
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Prof. Dr. Chunxue Bai
Jin-Ping Zheng,1,* Jing Zhang,2,* Li-Jun Ma,3 Ping Chen,4 Mao Huang,5 Xue-Mei Ou,6 Zi-Wen Zhao,7 Shu-Juan Jiang,8 Jie Cao,9 Wanzhen Yao2
1State Key Laboratory of Respiratory Disease, National Clinical Research Center, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of China; 2Department of Respiratory Medicine, Peking University Third Hospital, Beijing, People’s Republic of China; 3Department of Respiratory Medicine, Henan Provincial People’s Hospital, Henan, People’s Republic of China; 4Department of Internal Medicine, The Second Xiangya Hospital, Hunan, People’s Republic of China; 5Jiangsu Province Hospital, Jiangsu, People’s Republic of China; 6Department of Respiratory Medicine, West China Hospital, Chengdu, People’s Republic of China; 7Department of Respiratory Medicine, Guangzhou First People’s Hospital, Guangzhou, People’s Republic of China; 8Department of Respiratory Medicine, Shandong Provincial Hospital, Shandong, People’s Republic of China; 9Department of Respiratory Medicine, Tianjin Medical University General Hospital, Tianjin, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Wanzhen Yao
Department of Respiratory Medicine, Peking University Third Hospital, 49 North Garden Road, Beijing 100191, People’s Republic of China
Tel +86 156 1190 8216
Purpose: The current guidelines recommend the use of systemic corticosteroids (SCS) as the optimal treatment for acute exacerbations of chronic obstructive pulmonary disease (AECOPD). The aim of this real-world study was to evaluate whether nebulized budesonide (NBS) could also be used as an initial treatment for AECOPD.
Patients and methods: AECOPD patients initially treated with NBS or SCS (oral/intravenous) were enrolled. A large-scale, long-term multicenter cohort study of AECOPD patients was performed to analyze outcomes for each treatment (NCT02051166).
Results: Initial NBS and SCS treatment resulted in similar outcomes in terms of improvements in FEV1, PaO2, SaO2, and PaCO2. Disease severity affected outcome similarly in both groups. When the groups were stratified according to whether the initial treatment was subsequently intensified or reduced, more intubation was seen in the groups in which initial treatment was intensified. NBS escalation and SCS reduction groups spent more days in the hospital. The NBS escalation group was associated with the highest medical expenditure and a relatively higher rate of new-onset pneumonia. The NBS maintenance/reduction group showed the lowest mortality rate between groups. Stratification according to initial PaCO2 level showed more intubation in the groups with high initial PaCO2 concentrations.
Conclusion: These results indicate that NBS may be used as an initial treatment in certain AECOPD patients, and further studies are needed to better define those most likely to benefit.
Keywords: nebulized budesonide, systemic corticosteroids, chronic obstructive pulmonary disease, AECOPD
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]